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Should we discontinue 
Pap smear screening 
in women aged >65 years?
■ EVIDENCE-BASED ANSWER
Women with a history of regular, normal Pap
smear screening should discontinue screening by
age 65 years (strength of recommendation [SOR]:
B). Women without a history of serial normal Pap
smears should continue screening (SOR: B).
■ EVIDENCE SUMMARY
There is little direct evidence to support discon-
tinuation of Pap screening in older women, but
indirect evidence demonstrates that screening
has reduced value in women with a history of
periodic, normal Pap screening. 
A systematic review of 12 studies from 1995
to 2001, which included women aged 50 years
and older stratified by age and outcomes, showed
that the risk of high-grade cervical lesions falls
with age, and that a history of normal Pap tests
further reduces that risk.1 This observational evi-
dence is based on large population-based cohort
studies and a few prospective cohort studies. 
According to this review, fewer than 1 in 1000
(and possibly as few as 2 in 10,000) women aged
>60 years with a history of a normal baseline Pap
smear will develop cervical intraepithelial neo-
plasia (CIN) 3 or cancer. By comparison, women
being screened for the first time had rates of 
CIN 3 or cancer at 2.3 per 1000 for ages 50 to 
64 years, and 1.7 per 1000 for women aged 
65 years. 
A prospective study of older women (average
age, 66.7 years) followed for 2 years after a nor-
mal Pap smear result found an incidence of Pap
smear abnormalities of 110 per 4895 (23 per
1000 person-years; 95% confidence interval [CI],
18–27 per 1000), but only 1 result of the 110 was
a true positive (0.2 per 1000 person-years).2
A retrospective review of 798 cases of CIN or
worse diagnosed in Scotland from 1989 to 1990
found that 98% of CIN occurred in women aged
≤50 years.3 Given a low prevalence of true positive
high-grade Pap smears in elderly women with a
history of normal Pap smear results, elderly
women are disproportionately likely to have eval-
uations for false-positive results.1 With an esti-
mated sensitivity of 60% and specificity of 98%,
continued Pap screening would result in at least
34 elderly women being evaluated for high-grade
Pap smears for every 1 true positive; and for every
3 cases identified, 2 would be missed.1 As a com-
parison, for women of all ages with a high-grade
Pap smear, 70% to 75% will have CIN 2 or 3, and
1% to 2% will have invasive carcinoma.4
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cost-effectiveness of continued screening in 
elderly women who have not received adequate
screening previously, while showing high cost-to-
benefit ratio for continued screening in women
with previous normal Pap smear results. 
In a hypothetical cohort of elderly women who
were never screened, annual Pap smear screening
would cost less than $6500 per year of life saved.
The cost per year of life saved in women who have
received regular screening every 3 years would be
$33,572. 
■ RECOMMENDATIONS FROM OTHERS
The 2002 guidelines from the American Cancer
Society recommend that women aged 70 and
older who have had 3 consecutive normal Pap
smear results and no abnormal results in the past
10 years may choose to stop cervical cancer
screening.9 The 2003 guidelines from the US
Preventive Services Task Force recommend dis-
continuing Pap smear screening after age 65 if
previous Pap results were consistently normal.10
In 1994, the Canadian Task Force on Preventive
Health Care recommended stopping screening at
age 70 if women have had at least 4 negative Pap
smear results in the preceding 10 years and if pre-
vious results were normal.11 The American
College of Obstetrics and Gynecology recom-
mends physicians determine when to stop screen-
ing on an individual basis, and notes that limited
studies of older women made it difficult to set an
upper age limit for Pap smears.12
Medicare covers Pap smears every 3 years, but
will pay for yearly screening for women who have
had an abnormal Pap result in the preceding 3
years and for women at high risk of cervical or
vaginal cancer. 
Diana R. Curran, MD, Hendersonville Family Practice
Residency, Hendersonville, NC; Sue Stigleman, MLS,
Mountain Area Health Education Center, Asheville, NC
Several studies support the conclusion that
women aged >65 years without a history of 
regular normal Pap smear results continue to
benefit from cervical cancer screening. A
prospective study of an urban, low-income popu-
lation in New York (average age, 74) who were
previously inadequately screened (>5 years since
last Pap smear in 75%) or had no previous
screening (25%) found an incidence of 15.9 
per 1000 of abnormal Pap smear results (95% CI,
8.5–23.3).5
The results of Pap screening among older
women were analyzed in the retrospective review
from the population-based registry of the Ontario
Cervical Screening Program for almost 700,000
women screened during the first 6 months in
2000.6 In this population, over 80% of women
aged ≥50 years with high-grade lesion or carcino-
ma had a history of either no Pap screening or 
a previously abnormal test result in the past 
4 years. Nonparticipants in Pap screening had a
2.7 to 4 times greater risk of cervical cancer than
women screened at least once before.4
In the US, after Medicare began coverage for
Pap smear screening in women age 65 and older,
increased screening has resulted in more 
diagnoses of carcinoma in situ and a reduction in
cervical cancer.7
A cost-benefit analysis, designed and pub-
lished in 1992, evaluated Pap smear screening in
the elderly with a Markov mathematical model.
This model predicted the outcomes of periodic
screening, diagnosis, and treatment for cervical
cancer in hypothetical cohorts of women aged 
65 to 109 years.8 The Table depicts the cost 
per year of life saved for each Pap smear screen-
ing cohort of women analyzed in the Markov
mathematical model. These data demonstrate
A retrospective review found 
that 98% of CIN occured 
in women aged 50 years or more
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■ CLINICAL COMMENTARY
Stop Pap smears at 65 for those with 
normal prior screening, low risk for HPV
My older patients are delighted to stop hav-
ing Pap smears and want to quit as soon as
possible. The test can become quite an
ordeal with advancing age as cervical
stenosis, vaginal atrophy, and hip arthritis
increase patient discomfort and technical
difficulty. Following the lead of the US
Preventive Services Task Force, I stop rec-
ommending them at age 65 for most
patients who have a record of recent normal
Pap smear results.
However, older adults are sexual beings,
and HPV transmission can occur among
those who are sexually active outside a
long-term mutually monogamous relation-
ship. When counseling women with high-
risk lifestyles, I will discuss the possibility
of continuing regular Pap smears beyond 65
years of age.
Jon O. Neher, MD, Valley Medical Center Family
Practice Residency, Renton, Wash
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Cost-benefit analysis of Pap smear screening
Patient Screening frequency Cost per year of life saved
All women aged >65 years Every 3 years $7000 
Women aged >65 years without Every year <$6500
a previous Pap or Pap within 
5 years 
Women aged >65 years with Every 3 years $33,572
a history of normal, regular 
Pap smear results
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